

# Table of Contents

About the Editor and Authors	v
Foreword	xlv
List of Abbreviations	li
CHAPTER 1	
Overview of European Pharmaceutical Regulatory Requirements <i>Sally Shorthose</i>	1
§1.01 Introduction	1
[A] History of Pharmaceutical Regulation	1
[B] The European Union	3
[C] Major EU Pharmaceutical Legislation	4
[D] Key EU Pharmaceutical Reform Legislation	5
[E] National Law and Interface with EU Directives	6
§1.02 Definitions	6
[A] Medicinal Product	6
[B] Generic Medicinal Products	6
[C] Paediatric Medicines	7
[D] Orphan Drugs	7
[E] Biotechnology-Derived Medicinal Products	8
[F] Homeopathic Medicinal Products	8
[G] Herbal Medicinal Products	9
[H] Traditional Herbal Medicinal Products	9
[I] Radiopharmaceuticals	10
[J] Non-prescription Medicines	10
[K] Immunological Medicinal Products	11
[L] Medical Devices	12

## Table of Contents

---

§1.03	The Regulatory Agencies	12
	[A] The European Commission	12
	[1] DG Health and Consumers (Commonly Known as ‘SANCO’)	13
	[a] The Public Health Unit	14
	[b] Biotechnology	14
	[2] The European Medicines Agency	14
	[B] Committees of the EMA	15
	[1] The Committee for Medicinal Products for Human Use	15
	[2] The Committee for Medicinal Products for Veterinary Use	17
	[3] The Committee for Orphan Medicinal Products	17
	[4] The Committee on Herbal Medicinal Products	18
	[5] The Paediatric Committee	18
	[6] Committee for Advanced Therapies	19
	[7] Pharmacovigilance Risk Assessment Committee	20
	[C] The Heads of Medicines Agencies	21
	[D] National Competent Authorities of European Member States	21
	[E] Coordination Group for Mutual Recognition and Decentralised Procedures: Human (CMDh)	22
	[F] European Directorate for the Quality of Medicines	23
	[G] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use	23
§1.04	Applicable EU Legislation, Including Regulations and Guidance	24
	[A] EU Treaties	24
	[B] Directives	25
	[C] Regulations	25
	[D] The Official Journal of the European Communities	26
	[E] Guidelines	26
§1.05	Guidelines/Publications	28
CHAPTER 2		
Overview of Intellectual Property Rights		
	<i>Sally Shorthose &amp; Tasmina Goraya</i>	29
§2.01	Introduction	29
	[A] The Importance of Intellectual Property Rights	30
	[B] Ownership	30
§2.02	Patents	31
	[A] European Patents	32
	[1] Patentability and Scope of Protection	32
	[a] Requirements	33
	[b] Scope of Protection	33

Table of Contents

	[2] Prosecution and Enforcement	34
	[a] EPO Opposition Proceedings	35
	[b] National Courts	35
	[3] Duration	35
[B]	Specific Issues Relating to Pharmaceutical Patents	36
	[1] Product by Process	36
	[2] New Chemical Entities (NCEs)	36
	[3] Composition and Formulation Claims	37
	[4] Methods of Treatment	37
	[5] Medical Use	38
	[6] Biotechnological Inventions	39
[C]	Unitary Patent System	41
	[1] The Legislative Framework:	41
	[a] Legislative Instruments	41
	[b] Ratification	42
	[2] Unitary Patent	43
	[3] Unified Patent Court	43
	[4] Practical Considerations	44
	[a] Cost	44
	[b] Divisional Applications	44
	[c] Opting Out	44
	[d] Licences and Technology Transfer Agreements	45
§2.03	Supplementary Protection Certificates	45
§2.04	Trademarks	46
	[A] Registration of Trademarks	46
	[1] Routes to Registration	46
	[2] Criteria for Registration	47
	[a] Absolute Grounds	47
	[b] Relative Grounds	48
	[3] Duration	49
	[B] Regulatory Issues with Pharmaceutical Names	49
	[1] International Non-proprietary Names	49
	[2] Public Health Concerns and Patient Safety	50
	[a] Purely National, Mutual Recognition and Decentralised Procedures	51
	[b] Centralised Procedure	52
	[C] Infringement	53
§2.05	Copyright, Database Rights and Design Rights	53
	[A] Copyright	53
	[B] Database Rights	54
	[C] Design Rights	55
§2.06	Confidential information	55

## Table of Contents

---

CHAPTER 3		
Clinical Trials		
<i>Sally Shorthose</i>		57
§3.01	Introduction	57
§3.02	Directive 2001/20/EC: The Clinical Trials Directive ('CTD')	59
	[A] Introduction to the CTD	59
	[B] When the CTD Applies	59
	[C] Implementation of the CTD	60
	[D] Aims of the CTD	61
	[E] Revision of the CTD/Introduction of a New Regulation	62
§3.03	Preparing to Commence a Clinical Trial	62
	[A] Introduction to the Commencement of a Clinical Trial	62
	[B] The Sponsor	63
	[1] Overall Sponsor Duties	63
	[2] Duty to Create the Trial Protocol	64
	[3] Duty to Select an Investigator and an Institution	65
	[4] Duty to Create the Investigator's Brochure	66
	[5] Duty to Provide Quality Control	67
	[C] The Investigator	67
	[D] The Trial Identification Number	68
	[E] Advance Requests for EMA Advice	68
§3.04	Approval to Commence a Clinical Trial	69
	[A] Introduction to the Clinical Trial Approval Process	69
	[B] Ethical Committee Approval	70
	[1] Ethical Committee Approval Process	70
	[2] Informed Consent	71
	[3] The Ethical Committee Opinion	73
	[4] Ethical Committee Approval in Multi-State Trials	73
	[C] Trial Authorisation	74
§3.05	Conduct of the Clinical Trial	74
	[A] Introduction to the Conduct of Clinical Trials	74
	[B] GCP Standards	75
	[C] Good Manufacturing Practice	77
§3.06	Clinical Trial Oversight	79
	[A] Introduction to Clinical Trial Oversight	79
	[B] Monitoring	79
	[C] GCP Inspection	81
	[D] Internal Audit	82
	[E] Sponsor and Investigator as the Same Entity	82
	[F] Pharmacovigilance	83
§3.07	Trial Data	85
	[A] Introduction to Trial Data	85
	[B] Public Access to Trial Data	86
	[C] The Trial Master File: Essential Documents	87

Table of Contents

	[D] Collection of Data	88
	[E] Protection of Data and Storage Requirements	91
	[F] Retention of Data	92
§3.08	Trial Amendments and Termination	93
	[A] Introduction to Trial Amendments and Terminations	93
	[B] Amendments by the Ethics Committee or the Competent Authority	93
	[C] Amendments by the Sponsor	93
	[1] Notice of Amendment	94
	[2] Deviations	95
	[D] Termination of the Trial	95
§3.09	First-in-Man Studies Following the TGN1412 Case ('TeGenero')	95
	[A] New CHMP Guidelines as a Result of the TeGenero Case	97
§3.10	Updated Clinical Trials Guidance from European Commission	98
§3.11	The New Regulation of Clinical Trials on Medicinal Products for Human Use and Repealing Directive	99
	[A] The New Regulation on Clinical Trials on Medicinal Products for Human Use	100
	[1] Scope	100
	[B] Proportionality: 'Low-Intervention Clinical Trials'	101
	[C] New Procedures	101
	[1] The Authorisation Procedure	101
	[2] Summary of New Procedures	102
	[3] Application Dossier	103
	[4] The EU Portal and the European Medicines Agency Database for Safety Reporting	104
	[5] Sponsors	104
	[6] Ethics Committees	105
	[7] Damage Compensation and Fees	106
	[8] Inspections	106
	[9] Clinical Trials Coordination and Advisory Group	107
§3.12	Clinical Trials and Patent Legislation: The Bolar and Research Exceptions	107
§3.13	Guidelines/Publications	147
CHAPTER 4		
Obtaining a Marketing Authorisation		
<i>Sally Shorthose &amp; Sarah Faircliffe</i>		149
§4.01	Approval of Medicines for Human Use: Securing a Marketing Authorisation	149
	[A] Introduction and Overview of the Processes	149
	[B] Goals of the Approval Process: Demonstration of Quality, Safety, and Efficacy	150
	[C] Legislative Background	151

## Table of Contents

---

	[D] Overview of the Application Dossier	152
	[E] Overview of the Marketing Authorisation Procedures	152
§4.02	Requirements of the Application Dossier	153
	[A] Required Contents of an Application Dossier	154
	[1] Manufacturing Authorisations	155
	[2] Assurance of Quality of All Constituents	156
	[3] New Active Substances	157
	[4] Certificates of Suitability	157
	[5] Orphan Drugs	157
	[6] Naming the Product	158
	[7] Required Product Information	158
	[8] Summary of Product Characteristics	159
	[9] Environmental Risks	159
	[10] Pharmacovigilance Systems	159
	[11] Submission of Test Results	160
§4.03	[B] Presentation of the Dossier: The Common Technical Document	160
	The Centralised Procedure	162
	[A] Scope	162
	[1] Optional Scope	162
	[2] Mandatory Scope	163
	[B] Submission to the European Medicines Agency	163
	[C] Application and Approval Procedure: An Overview	164
	[1] The Committee for Medicinal Products for Human Use	165
	[2] Rapporteur of the CHMP	166
	[3] CHMP Assessment	166
	[4] Commission Decision	167
	[5] Withdrawal	168
	[6] Publication	168
	[D] Marketing	169
	[E] Special Procedures	169
	[1] Compassionate Use	169
	[2] Conditional/Exceptional Circumstances Authorisations	170
	[F] Timing of the Process	170
	[G] Alternatives to the Centralised Procedure	172
§4.04	Mutual Recognition Procedure	172
	[A] Introduction	172
	[B] Application Process	173
	[C] Dispute Procedure	174
	[D] Timing of the Process	175
§4.05	Decentralised Procedure	176
	[A] Introduction	176
	[B] Application Process	177
	[C] Dispute Procedure	177
	[D] Timing of the Procedure	177

Table of Contents

§4.06	The National Procedure	178
	[A] Introduction	178
	[B] Application Process	178
§4.07	Advantages and Disadvantages of the Four Procedures	179
	[A] The Centralised Procedure	179
	[B] The Mutual Recognition Procedure	180
	[C] The Decentralised Procedure	181
	[D] The National Procedure	181
§4.08	Continuing Validity, Renewal and Termination of Marketing Authorisations	182
§4.09	Guidelines/Publications	183
CHAPTER 5		
Conditional Marketing Authorisations		
	<i>Sally Shorthose</i>	185
§5.01	Introduction	185
§5.02	Criteria for a CMA	186
	[A] New Marketing Authorisation Applications	186
	[B] Justification that the Medicinal Product Falls within the Scope of a CMA	186
	[1] Seriously Debilitating Diseases or Life-Threatening Diseases	187
	[2] Medicinal Products to Be Used in Emergency Situations	188
	[a] Influenza Pandemic	188
	[b] Bioterrorism	189
	[3] Orphan Medicinal Products	190
	[C] Requirements for a CMA	190
	[1] The Risk/Benefit Balance of the Product Is a Positive	190
	[2] It Is Likely That the Applicant Will Be Able to Provide Comprehensive Data?	191
	[3] Fulfilment of Unmet Medical Need	192
	[4] The Benefits to Public Health of Immediate Availability Outweigh the Risks Inherent in the Fact That Additional Data Are Still Required	192
	[D] Specific Obligations	193
	[E] Timeframe	193
	[F] Amendment to Full Marketing Authorisation	193
§5.03	Procedure	193
	[A] Prior to Submission of a CMA	193
	[B] Timing of the Submission and Documentation to be Supplied	194
	[1] Documents to Be Submitted	194
	[a] General Requirements	194
	[b] Requirements for the Interim Report on the Specific Obligations	195

## Table of Contents

---

	[c] CHMP Assessment and Opinion	196
	[C] CHMP Assessment of a Request for a CMA	196
	[D] Information Included in the Summary of Product Characteristics and Package Leaflet	197
	[E] EMA Timetable	197
§5.04	Marketing Authorisation Granted in Exceptional Circumstances	198
§5.05	Guidelines/Publications	199
CHAPTER 6		
Supplementary Protection Certificates		
	<i>Tasmina Goraya</i>	201
§6.01	Introduction	201
§6.02	The Legislation	202
§6.03	Duration and Scope	204
	[A] Duration	204
	[1] Basic Term	204
	[2] Paediatric Extensions for Medicinal Product SPCs	205
	[B] Scope	205
	[1] What Is a 'Product'?	206
	[2] The Distinction between a 'Product' and a 'Medicinal Product'	208
§6.04	The Procedure for Seeking SPC Protection	208
§6.05	Infringement and Invalidation	210
§6.06	Transitional Provisions	211
§6.07	Issues in Relation to Supplementary Protection Certificates	213
	[A] When Is a Product 'Protected by a Basic Patent in Force'	213
	[1] Construction of Patent Claims	214
	[2] Combination Products	214
	[3] Amendments to the Basic Patent	216
	[4] Functional Specifications	217
	[5] Multiple SPCs Based upon a Single Patent	219
	[B] The Product Has Not Already Been the Subject of a Certificate	220
	[C] First Authorisation to Place the Product on the Market as a Medicinal Product	220
	[1] 'First Authorisation'	220
	[2] Date of First Authorisation	222
	[D] What Happens when the Basic Patent and Marketing Authorisation Have Different Holders?	222
	[E] What Form Can an SPC 'Claim' Take and What Effect Does It Have on the Scope of Protection Conferred?	223
§6.08	The Unitary Patent System and SPCs	224
	[A] European SPC	224
	[B] Unitary SPCs	225



CHAPTER 7		
Paediatrics		
	<i>Sally Shorthose &amp; Sarah Faircliffe</i>	227
§7.01	Introduction	227
§7.02	European Regulatory Law Relating to Paediatric Medicinal Products	228
	[A] Overview of the EU Paediatric Regulation	228
	[B] The Paediatric Committee	229
	[C] Paediatric Investigation Plans	230
	[1] PIP Approval Procedures	232
	[2] PIP Compliance Check	233
	[3] Issues concerning PIPs	234
	[D] PIP Exemptions, Waivers, and Deferrals	235
	[1] Exemptions	235
	[2] Waivers	236
	[3] Deferrals	236
§7.03	Rewards for PIP Completion	237
	[A] The Supplementary Protection Certificate Extension Reward	237
	[1] Zero and Negative Term SPCs	238
	[B] Rewards for Orphan Medicinal Products That Comply with Regulation (EC) No. 1901/2006	239
	[C] Free Scientific Advice from EMA	240
§7.04	Paediatric Use Marketing Authorisation (PUMA)	240
§7.05	Post-approval Obligations	241
	[A] Duty to Place Product on Market	241
	[B] Pharmacovigilance	241
	[C] Product Discontinuation	242
	[D] The Paediatric Symbol	242
§7.06	Penalties	243
§7.07	Transparency	243
§7.08	Paediatric Research	244
§7.09	Future Developments	245
§7.10	Guidelines/Publications	246
CHAPTER 8		
Advertising Medicinal Products for Human Use		
	<i>Anne-Charlotte Le Bihan &amp; Jean-Baptiste Thiénot (main chapter France), Sally Shorthose &amp; Sarah Faircliffe (UK), Marc Martens &amp; Nicolas Carbonnelle (Belgium), Ulf Grundmann (Germany), Hanneke Later-Nijland (Netherlands), Mauro Turrini (Italy), Gabriel Lidman (Sweden) and Raquel Ballesteros &amp; Lola Canalejo Rodriguez (Spain)</i>	249
§8.01	Introduction	249
§8.02	Legislative Basis	252
	[A] European Case Law on Advertising of Medicinal Products	252

## Table of Contents

---

	[B] The General Principles	255
	[C] Promotion of OTC Medicines	255
	[D] What Is Advertising?	257
	[E] Television Advertising	258
	[F] Proposals for Changes in the Legislation	259
§8.03	Self-regulation in Europe	260
	[A] Advertising of Prescription-Only Products	260
	[1] The EFPIA Code	260
	[2] Scope of the EFPIA Code	261
	[3] EFPIA Code and Websites	261
	[B] Advertising of OTC Products	261
§8.04	Implementation in the United Kingdom	262
	[A] Legal Basis	262
	[B] Scope of the Regulations	263
	[C] Regulation by the MHRA	264
	[1] The Blue Guide	265
	[2] Advertising Using the Internet	265
	[3] Complaints to the MHRA	266
	[D] Sanctions	267
	[E] Self-regulation	268
	[1] The ABPI and Prescription Medicines Code of Practice Authority	269
	[2] Proprietary Association of Great Britain (PAGB)	271
	[a] The PAGB Consumer Code	272
	[b] The PAGB Professional Code	272
	[F] Advertising Standards Authority	273
	[G] Association of British Healthcare Industries (ABHI)	274
§8.05	Implementation in Germany	274
	[A] Legal Basis	274
	[B] Scope of the Advertising of Medicinal Products Act	275
	[C] National Sanctions	276
	[D] Role of the National Competent Authority	276
	[E] National Implementation beyond Requirements of Directive 2001/83/EC	276
	[1] Testimonials	277
	[2] Internet Presentations	277
	[3] Further Requirements	277
§8.06	Implementation in the Netherlands	278
	[A] Legal Basis	278
	[1] The Medicines Act	278
	[2] Enforcement	278
	[3] Sanctions	279
	[4] Inspections	280
	[5] Cooperation with Other Regulating Institutes	280

Table of Contents

	[B] Civil Law	281
	[C] Criminal Law	281
	[D] Self-regulation	281
	[1] Enforcement	282
	[2] Sanctions	283
	[3] Advertising Code	283
	[a] Information	284
	[b] Comparative Advertising	284
	[c] Samples	284
	[d] Internet Advertising	285
	[4] OTC Advertising Code	285
	[5] Guidance Documents	286
	[a] Gifts	286
	[b] Hospitality	286
	[c] Sponsoring and Grants	287
	[d] Services	288
	[E] Medical Devices	289
	[F] Healthcare Products	289
§8.07	Implementation in Italy	289
	[A] Legal Basis	289
	[B] Scope of the Decree	290
	[C] Role of the National Competent Authority	290
	[D] Self-regulation for Promotion of Prescription-Only Products	291
	[E] Self-regulation for Promotion of OTC Products	291
	[F] General Advertising Rules	291
	[G] Regional Control	291
	[H] National Sanctions	292
	[I] Advertising on the Internet	292
§8.08	Implementation in Sweden	292
	[A] Legal Basis	292
	[B] Scope of the Regulations	293
	[C] Role of the MPA: The National Competent Authority	294
	[1] Complaints to the MPA	294
	[2] Sanctions	295
	[D] Self-regulation	296
	[1] The LIF	296
	[2] The Ethical Rules	296
	[3] The IGM and the NBL	297
	[4] The IGM	298
	[5] The NBL	299
	[6] Agreements on Forms of Collaboration with the Healthcare Sector	300
	[7] Other Applicable Rules	300
§8.09	Implementation in Belgium	301

## Table of Contents

---

	[A] Legal Basis	301
	[B] Sanctions	301
	[C] Role of the National Competent Authority	302
	[D] Self-regulation	302
	[E] Cases	302
	[F] General Advertising Rules	303
§8.10	Implementation in Spain	303
	[A] Regulatory Aspects	303
	[1] Legal Basis	303
	[2] The General Principles as Interpreted by Spanish Authorities	304
	[3] Advertising Aimed at Persons Qualified to Prescribe or Supply Medicinal Products	304
	[a] Advertising Using the Internet	305
	[4] Advertising Aimed at the General Public	306
	[B] Infringements and Remedies under the Law	307
	[C] Self-regulation	310
	[1] Spanish Code of Good Practice for the Pharmaceutical Industry	310
	[a] Promotion of Medicines and Interaction with Healthcare Professionals	311
	[b] Relationships between the Pharmaceutical Industry and Patient Organisations	312
	[2] Spanish Code of Good Practices for the Promotion and Advertising of Non-prescription Medicinal Products	313
	[D] Infringements and Remedies under the Farmaindustria Code	314
§8.11	Implementation in France	315
	[A] Legal Bases	315
	[1] Binding Rules	315
	[a] Drug Advertising	315
	[b] Medical Devices Advertising	316
	[2] Non-binding Rules	317
	[B] Regulation by the ANSM	318
	[1] Drug Advertising Directed at Healthcare Professionals	318
	[2] Drug Advertising Directed at the Public	319
	[3] Medical Devices	319
	[C] Specific Forms of Advertising	319
	[1] Meetings and Congresses	319
	[2] Bonus and Gifts	319
	[3] Samples of Medicinal Products	320
	[D] Sanctions	320
	[1] Administrative Sanctions	320
	[a] Control of Advertising Directed at the Public	320
	[b] Control of Advertising Directed at Healthcare Professionals	321

Table of Contents

	[2] Criminal Sanctions	321
§8.12	Future Developments	322
	[A] Introduction	322
	[B] Proposed Changes to Directive 2001/83/EC	322
	[C] Proposed Changes to Regulation 726/2004	323
Annex		325
CHAPTER 9		
Pharmacovigilance		
	<i>Sally Shorthose</i>	329
§9.01	Introduction	329
§9.02	Pre-authorisation Pharmacovigilance	333
	[A] Legislative Framework	333
	[B] First-in-Man Trials	336
	[1] Case Study 1	336
	[C] Clinical Trials in Patients	337
	[D] The Investigator Brochure	337
	[E] Reporting SUSARs	337
§9.03	The Marketing Authorisation Application	338
	[A] Legislative Framework	339
	[B] The Requirements Set Out in Directive 2001/83/EC	341
	[C] The Reporting of Adverse Reactions	342
	[1] Reports to the Marketing Authorisation Holder	342
	[2] Reports from Patients/Consumers	344
	[3] Reports with Name of Active Substance Only	345
	[4] Literature Reports	345
	[5] Reports from Non-medical Sources	346
	[6] Timescales for Expedited Reporting	346
	[7] MedDRA	347
	[8] Electronic Reporting	347
	[9] Pregnancy Registries	348
	[10] Lack of Efficacy	348
	[11] Abuse, Misuse, or Overdose	348
	[12] Public Health Emergency	349
§9.04	Periodic Safety Update Reports	349
	[A] Introduction	349
	[B] Contents of the PSUR	349
	[C] Periodicity of Submission of PSUR	350
	[D] PSUR Work-Sharing Initiative	351
§9.05	The Pharmacovigilance Activities of the Key Parties	352
	[A] The EMA	352
	[B] Pharmacovigilance Working Party	353
	[C] Competent Authorities of the Member States	353
§9.06	Risk Management and EU-RMP	357

## Table of Contents

[A]	Introduction	357
[B]	Content of the EU-RMP	357
[C]	Monitoring of the Risk/Benefit Balance and Identification of Safety Signals	358
[D]	Risk Management at the Marketing Authorisation Holder's Initiative	359
[E]	Risk Management at the EMA's Initiative	359
[1]	Case Study 2: Cerivastatin (Lipobay) Withdrawal	360
[F]	Risk Management at National Competent Authorities' Initiative	362
[1]	Case Study 3: Bupropion	362
§9.07	Compliance with Pharmacovigilance Obligations	362
[A]	Legal Basis for Pharmacovigilance Inspections	364
[B]	Composition of the Inspection Team	365
[C]	Timing of Inspections	365
[D]	Conduct of Pharmacovigilance Inspections	366
[E]	Common Findings of Inspections	368
[F]	Sanctions	369
§9.08	Summary of Recent Changes	371
[A]	Pharmacovigilance System Master File	371
[B]	Co-Ordination and Inspection: Pharmacovigilance Risk Assessment Committee (PRAC)	372
[C]	Post-Authorisation Safety Studies and Post-Authorisation Efficacy Studies	375
[D]	Specific Conditions Relating to PhV affecting EMA	375
[1]	PSUR Requirements	376
[2]	Set-up of Interconnected Web-Portals	376
[3]	GVP Guidelines	376
§9.09	Guidelines/Publications	378
CHAPTER 10		
Variations to Marketing Authorisations		
	<i>Tasmina Goraya</i>	381
§10.01	Reason for Variations	381
[A]	Changes Not Requiring a Variation	382
[B]	Variation Legislation	382
§10.02	Classification of Changes	382
[A]	Types IA and IB	383
[1]	Type IA	383
[2]	Type IB	383
[3]	Re-classification of Type IA and Type IB variations	384
[B]	Type II	384
[1]	Definition	384
[2]	Type II Categories	384
[3]	The ICH Design Space Concept	385

Table of Contents

	[a]	Introduction	385
	[b]	Process Analytical Technology	385
	[c]	Quality Risk Management	385
	[C]	Extensions	386
	[1]	Changes in Pharmaceutical Form	386
	[2]	Changes in Strength	387
	[D]	Classification of Unforeseen Variations	387
§10.03		Substantive Requirements of the Variation Application	388
	[A]	Variation Applications for Biological Medicinal Products	388
	[1]	Issues Arising in Relation to Biologicals	388
	[2]	Regulatory Guidelines	389
	[a]	Quality Guidelines	389
	[b]	Safety and Efficacy Requirements	390
§10.04		Variation Application Procedure	391
	[A]	Forms and Format	391
	[B]	Grouping of Applications	391
	[1]	Grouping of Variations Granted under the Mutual Recognition, Decentralised and Centralised Procedures	391
	[2]	Grouping of Variations to Purely National Marketing Authorisations	392
	[C]	Work-Sharing Procedure	393
	[D]	Products Authorised through Mutual Recognition	394
	[1]	Type IA	394
	[2]	Type IB	395
	[3]	Type II	396
	[E]	Centrally Authorised Products	397
	[1]	Advance Notice	397
	[2]	Type IA and IB Variations	397
	[3]	Type II Variations	398
	[F]	Purely National Procedure	399
	[1]	Type IA Variations	399
	[2]	Type IB Variations	399
	[3]	Type II Variations	399
	[G]	Urgent Safety Restrictions	400
	[H]	Human Influenza Vaccines	401
CHAPTER 11			
Combination Products			
		<i>Sarah Faircliffe</i>	403
§11.01		Introduction	403
§11.02		Requirements for Marketing Approval of Fixed-Combination Medicinal Products	405
	[A]	The Application Dossier	405
	[B]	The Application Procedure	405

## Table of Contents

[C]	Scientific References, Non-Clinical Trials, and Clinical Trials	406
[D]	Necessity of Non-clinical and Clinical Trials	407
[1]	Situations Where Additional Studies Are Necessary	408
[2]	Situations Where Fewer Studies Are Necessary	408
[a]	Combinations Already Approved as Free Combination Therapy	408
[b]	Combination of the Components Already Approved as a Fixed-Combination Product	410
§11.03	Criteria for Approval of Fixed-Combination Medicinal Products	411
[A]	The Risk/Benefit Ratio	411
[B]	Relevance of Each Active Substance of the Combination	411
[C]	Relevance of the Specific Dosage Regime	412
§11.04	Regulatory Variations for Fixed-Combination Products in Eight Key EU Jurisdictions	412
§11.05	Guidelines/Publications	417
CHAPTER 12		
Abridged Procedure		
<i>Hanneke Later-Nijland</i>		
§12.01	Introduction	419
§12.02	Three Types of Abridged Procedures	420
[A]	Abridged Procedure Based on Cross-Reference to Data with Holder's Consent	421
[B]	Abridged Procedure Based on Bibliographic Application for Well Established Use	422
[1]	Well-Established Medicinal Use	422
[2]	Ten Years of Use	423
§12.03	Abridged Procedure for Generic Products	423
[A]	Data Protection of a Registration File for 6 or 10 Years	424
[B]	Data Protection and Marketing Exclusivity, 8 + 2 Years	426
[C]	Data Protection Rules Applicable within the EU until 30 October 2015	427
[D]	European Reference Medicinal Product	428
[1]	Global Marketing Authorisation	430
[2]	Reference to Products Authorised in the Member States Cyprus, Lithuania, Malta, Poland and Slovenia	431
[3]	Similar Biological Medicinal Products	431
[E]	Essential Similarity and Generic Medicinal Product	432
[1]	Development of 'Essentially Similar' and Scope of Abridged Procedure for Generic Medicinal Products up to October/November 2005	432
[a]	Meaning of 'Essential Similarity'	432
[b]	Scope of Application of the Hybrid Abridged Procedure	434



Table of Contents

	[c] Essential Similarity and Line Extensions	435
	[d] Differences in Active Substance	436
	[e] Safety and Efficacy	436
[F]	Abridged Procedures for Generic Medicinal Products after October 2005	437
	[1] Definition of 'Generic Product' (Instead of 'Essentially Similar')	437
	[a] Same Qualitative and Quantitative Composition	438
	[b] Same Pharmaceutical Form	438
	[c] Bioequivalence Demonstrated by Studies	438
	[d] Salts, Esters, Ethers, Isomers, Mixtures, Complexes or Derivations	439
	[e] The Hybrid Procedure	439
	[f] New Active Substance	440
[G]	Additional Terms for Protection of Line Extensions	441
	[1] Extension for New Therapeutic Indication	442
	[a] Justification of New 'Therapeutic Indication'	442
	[b] Justification of 'Significant Clinical Benefit'	443
	[2] Extension for New Indications for Well-Established Substances	444
	[3] Change of Supply Status	445
CHAPTER 13		
Orphan Drugs		
<i>Sarah Faircliffe</i>		
		447
§13.01	Introduction	447
§13.02	The EU Orphan Drug Laws	448
§13.03	Applications for Orphan Designation	448
	[A] Pre-application Meeting	449
	[B] Application Contents and Format	449
	[C] Application Review: The Committee for Orphan Medicinal Products (COMP)	450
	[D] Criteria for Orphan Designation	451
	[1] Medicinal Product	451
	[2] Article 3(1) Requirements	451
	[3] Article 3(1)(a) Requirements	452
	[a] The Prevalence Criterion	452
	[b] The Insufficient Return on Investment Criterion	454
	[c] Medical Plausibility	456
	[4] Article 3(1)(b) Requirements	456
	[a] Existing Satisfactory Method	457
	[b] Significant Benefit Assumption	458
[E]	Clinical Data at the Designation Stage	460

## Table of Contents

---

[F]	Timing of Designation Applications	460
[G]	Application Approval and Appeal Process	461
[H]	Annual Review	461
[I]	Amendment of a Designation	461
§13.04	Orphan Medicinal Product Marketing Authorisation	462
[A]	The Centralised Procedure	462
[B]	Confirmation of Orphan Designation Criteria	462
§13.05	Market Exclusivity and Other Incentives	463
[A]	Protocol Assistance and Fee Reductions	463
[B]	Market Exclusivity	464
[1]	Meaning of ‘Similar Medicinal Product’	465
[2]	‘Breaking’ Market Exclusivity	465
[3]	Procedure for Assessing Similarity and Derogations	466
[4]	Impact of a Second Orphan Authorisation Granted under the Derogation Provisions	467
[a]	Case T-140/12, Teva v. EMA	468
[b]	Case T-452/14, Laboratoires CTRS v. European Commission	469
[C]	Market Exclusivity Review: Possible Reduction in Term	470
§13.06	Transfer of Orphan Designation	471
§13.07	Transparency	472
§13.08	Research	473
§13.09	Future Developments	474
§13.10	Guidelines/Publications	475
CHAPTER 14		
Biopharmaceuticals		
<i>Marc Martens &amp; Nicolas Carbonnelle</i>		477
§14.01	Introduction	477
§14.02	Specific Nature of Biopharmaceuticals and Consequences	478
[A]	Biological Starting Materials	478
[B]	Product Complexity and Variability	478
[C]	Possible Immunogenicity	479
§14.03	Market Access for Innovative Biologicals	479
[A]	Marketing Authorisation Application Routes	479
[B]	Marketing Authorisation Dossier	480
[1]	General Requirements Applicable To All Biological Medicinal Products	480
[2]	Information concerning the Active Substance	480
[3]	Manufacturing Process of the Active Substance	480
[4]	Description and Composition of the Finished Medicinal Product	481
[5]	Non-clinical Aspects	482
§14.04	Clinical Trials	482

Table of Contents

§14.05	Product-Specific Requirements	483
	[A] Plasma-Derived Medicinal Products	483
	[B] ATMPs	484
	[C] Vaccines	485
§14.06	Specific Market Surveillance Measures Applicable to Biological Medicinal Products	485
	[A] Pharmacovigilance Requirements	485
	[B] Changes to the Manufacturing Process	485
§14.07	Regulatory Data Protection	486
§14.08	The EMA'S Biologics Working Party	486
§14.09	Biosimilars	487
	[A] Concept of 'Biosimilar'	487
	[B] Generics versus Biosimilars	488
	[C] 'Me-Betters'	489
	[D] MAA Route	490
	[E] MAA Dossier Requirements	490
§14.10	Strategic Issues and Next Steps	492
CHAPTER 15		
Homeopathic, Herbal, and Traditional Herbal Medicinal Products		
	<i>Hanneke Later-Nijland</i>	495
§15.01	Introduction to Homeopathic, Herbal, and Traditional Herbal Medicinal Products	495
§15.02	Homeopathic Medicinal Products	497
	[A] Introduction to Homeopathic Medicinal Products	497
	[B] Legal History of Homeopathic Medicinal Products	498
	[C] Current Legislative Framework for Homeopathic Medicinal Products	499
	[D] Definition of Homeopathic Medicinal Product	499
	[E] Homeopathic Simplified Registration Procedure	500
	[F] Application Procedure for Homeopathic Simplified Registration	501
	[G] Article 16 Authorisation Procedure	502
	[H] Applicability of Other Provisions of the Directive for Homeopathic Medicinal Products	503
§15.03	Herbal and Traditional Herbal Medicinal Products	504
	[A] Introduction to Herbal and Traditional Herbal Medicinal Products	504
	[B] Herbal Medicinal Products	505
	[1] Definition of Herbal Medicinal Products	505
	[2] General Marketing Authorisation Procedure for Herbal Medicinal Products	505
	[C] Traditional Herbal Medicinal Products	506
	[1] Current Legislative Framework for Traditional Herbal Medicinal Products	506

## Table of Contents

	[2] Definition of Traditional Herbal Medicinal Products	506
	[3] Traditional Use Registration	506
	[4] Application Procedure for Traditional Use Registration	508
	[5] Labelling, Package Leaflet, and Advertising of Traditional Herbal Medicinal Products	510
	[6] Other Applicable Provisions for Traditional Use Registration	510
[D]	Safety and Efficacy of Herbal and Traditional Herbal Medicinal Products	511
[E]	Manufacturing and Quality of Herbal and Traditional Herbal Medicinal Products	511
[F]	Committee on Herbal Medicinal Products (HMPC)	512
[G]	Community Herbal Monograph	513
[H]	Community List	514
CHAPTER 16		
	Advanced Therapy Medicinal Products	
	<i>Marc Martens &amp; Nicolas Carbonnelle</i>	515
§16.01	Introduction	515
	[A] History	515
	[B] Definitions	517
	[1] Gene Therapy Medicinal Products (Section 2.1, Part IV, Annex I to Directive 2001/83/EC)	517
	[2] Somatic Cell Therapy Medicinal Products (Section 2.2, Part IV, Annex I to Directive 2001/83/EC)	517
	[3] Tissue-Engineered Products (Article 2 (b) of the ATMP Regulation)	518
	[C] Combined ATMPs and the Classification Rules	519
	[1] Combined ATMPs	519
	[2] Classification Rules	520
§16.02	Relationship between the ATMP Regulation and Other European Legislation	521
§16.03	The Market Access for ATMPs	523
	[A] Ordinary Regime	523
	[1] The Procedure	523
	[2] The Committee for Advanced Therapies	523
	[a] Role and Responsibilities	524
	[b] Composition	524
	[B] Exemptions	525
§16.04	The Marketing Authorisation Application Dossier	526
	[A] Specific Requirements Set Out in Part IV of Annex I to Directive 2001/83/EC	526
	[B] Other Requirements Applicable to ATMPs	528

Table of Contents

	[1] Summary of Product Characteristics, Labelling and Package Leaflet	528
	[2] Post-authorisation Requirements	528
	[a] Follow-Up of Efficacy and Risk Management	528
	[b] Traceability	529
§16.05	Incentives for Small and Medium Sized Enterprises	529
§16.06	Transitional Period	530
§16.07	Perspectives	530
§16.08	Conclusion	531
CHAPTER 17		
Vaccines		
	<i>Raquel Ballesteros</i>	533
§17.01	Introduction	533
	[A] General Overview	533
	[B] Vaccines Working Party	534
§17.02	Development of Vaccines	535
	[A] Non-clinical Aspects	535
	[1] Basic Science Phase	535
	[2] Pre-Clinical Testing	536
	[B] Clinical Trials	537
	[1] Pharmacokinetic/Pharmacodynamic Studies	539
	[2] Efficacy and Effectiveness	540
	[3] Special Considerations for Vaccine Development	541
§17.03	Marketing Authorisation Application	542
	[A] The Marketing Authorisation Procedures	542
	[1] Centralised	542
	[2] National	543
	[3] Decentralised and Mutual Recognition	543
	[B] Marketing Authorisation Applications (MAAs)	543
	[1] Module 1	543
	[2] Module 2	544
	[3] Module 3	544
	[4] Module 4	545
	[5] Module 5	545
§17.04	The Official Control Authority Batch Release	546
§17.05	Post-Marketing Surveillance: Pharmacovigilance	548
	[A] Some Institutions That Ensure Post-authorisation Safety of Vaccines	549
	[B] GVP Module for Vaccines	550
	[C] Post-marketing Authorisation Approval Requirements	552
	[1] Risk Management Plan	552
	[2] Variation of the Original VAMF Certificate	552

## Table of Contents

---

	[3] License Renewals	553
§17.06	The Special Case of the Influenza Vaccine	553
	[A] The Marketing Authorisation Application and Annual Update	554
	[1] Inactivated Influenza Vaccines	554
	[2] Live Attenuated Influenza Vaccines	555
	[B] Influenza Pandemic Planning	555
§17.07	Future Developments	556
§17.08	Guidelines/Publications	557
CHAPTER 18		
Medical Devices		
	<i>Ulf Grundmann &amp; Elisabeth Kohoutek</i>	561
§18.01	Introduction	561
§18.02	Medical Devices	562
	[A] European Legal Provisions	562
	[B] Definition of Medical Device	563
	[C] Borderline Products	564
	[1] Legislative Guidance	565
	[2] Judicial Guidance	565
	[D] Classification of Medical Devices	568
	[E] Essential Requirements for Marketing of Medical Devices	569
	[F] Conformity Assessment Procedures	570
	[G] Marketing Authority: Notified Bodies	571
	[H] CE Marking	573
	[1] CE Labelling	574
	[2] Value of the CE Marking	575
	[3] Misconceptions Regarding CE Marking	575
	[I] Registration of Persons Placing Medical Devices on the Market	576
	[J] Vigilance Procedure	577
	[K] Surveillance Role of Member States and Competent Authorities	578
	[L] Institutes, Organisations, and Associations	579
§18.03	In Vitro Diagnostic Medical Devices	580
	[A] Essential Requirements for Marketing in Vitro Diagnostic Medical Devices	580
	[B] Requirements for Marketing In Vitro Medical Devices for Self-testing	581
	[C] Conformity Assessment Procedures	583
	[1] Obligations of the Manufacturer	583
	[2] Obligations of Parallel Traders	584
	[D] Vigilance Procedure	585
§18.04	Active Implantable Medical Devices	585
	[A] Essential Marketing Requirements for Active Implantable Medical Devices	586
	[B] Vigilance Procedure	587

Table of Contents

§18.05	How to Advertise Medical Devices	587
	[A] German Provisions Regarding the Advertising of Medical Devices	588
	[1] Misleading Claims	589
	[2] Citations of Scientific Studies and Expert Opinions	589
	[3] Give-Aways	590
	[4] Testimonials	591
	[B] Unfair Competition Law Provisions and Codes of Conduct	591
§18.06	Future Developments	592
§18.07	Guidelines/Publications	607
CHAPTER 19		
Parallel Trade		
	<i>Hanneke Later-Nijland</i>	609
§19.01	Introduction to Parallel Trade	609
§19.02	Parallel Distribution Law	610
	[A] EMA Notice	610
	[B] Necessary Licenses for Parallel Distributors	611
	[C] Other Requirements	612
	[1] Changes in the Package or Label	612
	[2] Notice to Local Authorities	613
	[3] Marketing Authorisation Updates	613
	[4] Maintenance Notice	613
	[5] Quality Control	614
	[6] Falsified Medicines	614
§19.03	Parallel Importation	615
	[A] Parallel Importation Law	615
	[B] The Simplified Procedure	616
	[C] General Requirements for the Simplified Procedure	618
§19.04	Intellectual Property Law	619
	[A] Introduction	619
	[B] Patent Rights and Parallel Trade	619
	[1] Exhaustion of Patent Rights	620
	[2] Specific Mechanism	621
	[C] Trademark Law and Parallel Trade	624
	[1] The Repackaging Does Not Affect the Product	625
	[2] The Repackaging Is Not Likely to Damage Reputation	626
	[3] Indication of the Original Manufacturer and the Repackager	626
	[4] Notice to the Trademark Owner	626
	[5] The Repackaging Is ‘Necessary’	627
	[6] Burden of Proof	627
	[7] Rebranding	628

## Table of Contents

---

§19.05	Competition Law	628
§19.06	Regulatory Variations for Parallel Imports in Eight Key EU Jurisdictions	629
§19.07	Guidelines/Publications	644
CHAPTER 20		
Competition Law in the Pharmaceutical Sector		
<i>José Rivas, Carmen Feito &amp; Eleftheria Diamanti</i>		
§20.01	Introduction	645
§20.02	Market Definition in the Pharmaceutical Sector	645
	[A] Approved Medicines	646
	[B] Active Substances	647
	[C] Pipeline Products	647
§20.03	Article 101 of the TFEU	647
	[A] The Application of Article 101(1) TFEU	647
	[1] The Definition of an Undertaking	648
	[2] Definition of Agreements, Concerted Practices, and Decisions of Associations	649
	[a] Agreements	649
	[b] Concerted Practices	650
	[c] Decisions by Association of Undertakings	650
	[3] A Restriction of Competition by Object or Effect	650
	[4] An Appreciable Restriction of Competition: <i>De Minimis</i>	651
	[5] An Appreciable Effect on Trade between Member States	651
	[B] The Application of Article 101(3) TFEU	652
	[1] Individual Exceptions	652
	[2] Block Exemptions	653
	[a] The Block Exemption Regulation on Technology Transfer (TTBER)	653
	[b] The Block Exemption Regulation on Research and Development	654
	[C] Selection of Cases/The Pharmaceutical Sector Inquiry	656
	[1] Agreements between Originators and Generics	656
	[D] Reverse Payment Patent Settlements	656
	[E] Other Agreements Having the Effect of Delaying Generic Market Entry	657
	[1] Other Anticompetitive Agreements	658
§20.04	Article 102 of the TFEU	658
	[A] Establishing Dominance under Article 102	659
	[B] Abuse of a Dominant Position	660
	[1] Non-price-based Exclusionary Conduct	661
	[a] Misuse of IP Rights	661
	[b] Refusal to Supply	662



Table of Contents

	[c] Other Non-price-based Exclusionary Abuses	663
	[2] Price-Based Exclusionary Conduct	663
	[a] Fidelity Rebates and Exclusive Purchase Obligations	663
§20.05	Parallel Trade	664
§20.06	The EU Merger Control Regulation	666
	[A] Merger Control Procedure	666
	[B] Substantive Assessment	667
	[1] Horizontal Mergers	667
	[2] Non-horizontal Mergers	668
	[C] Selection of Cases	668
	[1] GlaxoWellcome/Smithkline Beecham	669
	[2] Novartis/Hexal	669
§20.07	State Aid	670
	[A] Definition of State Aid under the Treaty	670
	[B] Exemptions	671
§20.08	Guidelines/Publications	673
	Appendix Guidelines and Publications	675
	Table of Cases	689
	Directives	699
	Other Legislation	705
	Regulations	709
	Index	713